Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone

Aims and background In order to increase the prognostic significance of polymerase chain reaction (PCR) data it has been suggested that quantitative PCR can be used to measure tumor burden. However, this option has not yet been definitely supported or refuted in patients with follicular lymphoma (FL). We decided to evaluate whether knowledge of the quantitative level of minimal residual disease and its variations can be of use in the management of FL patients. Methods We used qualitative and competitive PCR to study 11 patients with refractory or relapsed FL harboring the t(14;18) translocation who underwent autologous (nine patients) or allogeneic (two patients) stem cell transplantation (SCT). Competitive PCR was performed with a multiple competitor carrying specific sequences including Bcl2/lgH MBR and mcr, and the β-globin gene. Results After a median post-SCT follow-up of 44 months (range, 12-62), overall survival was 91% and disease-free survival 82%. The quantitative PCR data showed that: 1) effective chemotherapy before SCT substantially (1-2 log) reduced the tumor burden in the bone marrow (BM); 2) the increase in rearranged DNA detected in BM was associated with disease progression and relapse; 3) a PCR-negative autograft seemed to lead to lasting molecular remission even when it was performed in patients with a low level of BM infiltration before transplant; and 4) allo-SCT made and maintained the BM PCR negative even in the presence of a greater tumor burden before SCT. Six of the nine patients having CR after SCT (four auto and two allo) are in continuous molecular remission. Conclusions In FL patients qualitative and quantitative PCR may provide data that can be helpful for the prognostic evaluation of tumor progression and the early detection of impending relapse by highlighting biological features such as the quality of the infused material, the tumor burden at transplant, and the behavior of tumor cells after transplant.

Download Full-text

Relationship between leukocyte, neutrophil, lymphocyte, platelet counts, and neutrophil to lymphocyte ratio and polymerase chain reaction positivity

International Immunopharmacology ◽

10.1016/j.intimp.2021.107390 ◽

2021 ◽

Vol 93 ◽

pp. 107390

Author(s):

M. Kabak ◽

B. Çil ◽

I. Hocanlı

Keyword(s):

Polymerase Chain Reaction ◽

Neutrophil To Lymphocyte Ratio ◽

Chain Reaction ◽

Lymphocyte Ratio ◽

Platelet Counts ◽

Polymerase Chain Reaction Positivity ◽

Polymerase Chain

Download Full-text

Clinical Significance of Minimal Residual Disease in Leukemia Detected by Polymerase Chain Reaction: Is Molecular Remission a Milestone for Achieving a Cure?

Leukemia & Lymphoma ◽

10.3109/10428199409114140 ◽

1994 ◽

Vol 16 (1-2) ◽

pp. 57-64 ◽

Cited By ~ 10

Author(s):

Yoshinori Ito ◽

Koichi Miyamura

Keyword(s):

Polymerase Chain Reaction ◽

Minimal Residual Disease ◽

Clinical Significance ◽

Residual Disease ◽

Molecular Remission ◽

Chain Reaction ◽

Polymerase Chain ◽

Minimal Residual

Download Full-text

Distinguishing repeated polymerase chain reaction positivity from re‐infections in COVID‐19

Influenza and Other Respiratory Viruses ◽

10.1111/irv.12883 ◽

2021 ◽

Author(s):

Sara Sadr ◽

Melika Arab Bafrani ◽

Alireza Abdollahi ◽

Seyed Ahmad SeyedAlinaghi ◽

Esmaeil Mohammadnejad ◽

...

Keyword(s):

Polymerase Chain Reaction ◽

Chain Reaction ◽

Polymerase Chain Reaction Positivity ◽

Polymerase Chain

Download Full-text

Quantitative PCR Analysis for Bcl-2/IgH in a Phase III Study of Yttrium-90 Ibritumomab Tiuxetan As Consolidation of First Remission in Patients With Follicular Lymphoma

Journal of Clinical Oncology ◽

10.1200/jco.2009.22.6258 ◽

2009 ◽

Vol 27 (36) ◽

pp. 6094-6100 ◽

Cited By ~ 31

Author(s):

Lindsey Goff ◽

Karin Summers ◽

Sameena Iqbal ◽

Jens Kuhlmann ◽

Michael Kunz ◽

...

Keyword(s):

Polymerase Chain Reaction ◽

Follicular Lymphoma ◽

Quantitative Polymerase Chain Reaction ◽

Phase Iii ◽

Pcr Analysis ◽

Control Group ◽

Ibritumomab Tiuxetan ◽

Chain Reaction ◽

Polymerase Chain ◽

Yttrium 90

Purpose The randomized First-Line Indolent Trial (FIT) was conducted in patients with advanced follicular lymphoma (FL), to evaluate the safety and efficacy of yttrium-90 (90Y) ibritumomab tiuxetan given as consolidation of complete or partial remission. This study of minimal residual disease was undertaken in parallel, to determine the rate of conversion from bcl-2 polymerase chain reaction (PCR) –detectable to –undetectable status and the corresponding effect on progression-free survival (PFS). Patients and Methods Blood samples from 414 patients (90Y-ibritumomab, n = 208; control, n = 206) were evaluated using real-time quantitative polymerase chain reaction (RQ-PCR); 186 were found to have the bcl-2 rearrangement and were thus eligible for inclusion in the RQ-PCR analysis. Results Overall, 90% of treated patients converted from bcl-2 PCR–detectable to –undetectable disease status, compared with 36% in the control group. Treatment significantly prolonged median PFS in patients converting to bcl-2 PCR-undetectable status (40.8 v 24.0 months in the control group; P < .01, hazard ratio [HR], 0.399). In patients who had bcl-2 PCR-detectable disease at random assignment, treatment significantly prolonged median PFS (38.4 v 8.2 months in the control group; P < .01, HR, 0.293). Conclusion Eradication of PCR-detectable disease occurred more frequently after treatment with 90Y-ibritumomab tiuxetan and was associated with prolongation of PFS.

Download Full-text